Intracranial anaplastic hemangiopericytoma presenting with simultaneous extra-cranial metastases: A case report and review of the literature.
Extracranial metastasis
Hemangiopericytoma
Intracranial
Simultaneous
Solitary fibrous tumor
Synchronous
Journal
Surgical neurology international
ISSN: 2229-5097
Titre abrégé: Surg Neurol Int
Pays: United States
ID NLM: 101535836
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
02
2019
accepted:
06
06
2019
entrez:
19
9
2019
pubmed:
19
9
2019
medline:
19
9
2019
Statut:
epublish
Résumé
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare mesenchymal tumor with a propensity to recur and metastasize extracranially years after treatment. Accordingly, there are no reported cases of a patient presenting with a simultaneous intracranial primary and extracranial metastases. We present the case of a patient presenting with an intracranial SFT/HPC and simultaneous liver metastases and propose a treatment paradigm. A 74-year-old male smoker presented with confusion. An MRI of the brain revealed a heterogeneously enhancing left frontal extra-axial mass. Systemic workup revealed multiple small liver lesions concerning for metastases. The patient underwent gross total resection (GTR) of the intracranial lesion with adjuvant CyberKnife stereotactic radiotherapy to the resection cavity. Pathology was consistent with a WHO Grade III SFT/HPC (previously known as anaplastic HPC). The liver lesions were biopsied and confirmed to be metastases. They were subsequently treated with stereotactic body radiation therapy, temozolomide, and bevacizumab. Eighteen months postoperatively, the patient is alive with no evidence of intracranial malignancy and regression of the hepatic lesions. Several studies support GTR and adjuvant radiotherapy to treat intracranial SFT/HPC. The role of adjuvant chemotherapy is less clear. Metastatic disease is typically detected several years after the initial diagnosis, and there is no consensus regarding the optimal treatment strategy. We propose that the rare presentation of intracranial SFT/HPC with simultaneous extracranial metastases should be treated in a multidisciplinary fashion with surgical resection, adjuvant radiotherapy, and chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare mesenchymal tumor with a propensity to recur and metastasize extracranially years after treatment. Accordingly, there are no reported cases of a patient presenting with a simultaneous intracranial primary and extracranial metastases. We present the case of a patient presenting with an intracranial SFT/HPC and simultaneous liver metastases and propose a treatment paradigm.
CASE DESCRIPTION
METHODS
A 74-year-old male smoker presented with confusion. An MRI of the brain revealed a heterogeneously enhancing left frontal extra-axial mass. Systemic workup revealed multiple small liver lesions concerning for metastases. The patient underwent gross total resection (GTR) of the intracranial lesion with adjuvant CyberKnife stereotactic radiotherapy to the resection cavity. Pathology was consistent with a WHO Grade III SFT/HPC (previously known as anaplastic HPC). The liver lesions were biopsied and confirmed to be metastases. They were subsequently treated with stereotactic body radiation therapy, temozolomide, and bevacizumab. Eighteen months postoperatively, the patient is alive with no evidence of intracranial malignancy and regression of the hepatic lesions.
CONCLUSION
CONCLUSIONS
Several studies support GTR and adjuvant radiotherapy to treat intracranial SFT/HPC. The role of adjuvant chemotherapy is less clear. Metastatic disease is typically detected several years after the initial diagnosis, and there is no consensus regarding the optimal treatment strategy. We propose that the rare presentation of intracranial SFT/HPC with simultaneous extracranial metastases should be treated in a multidisciplinary fashion with surgical resection, adjuvant radiotherapy, and chemotherapy.
Identifiants
pubmed: 31528483
doi: 10.25259/SNI_111_2019
pii: SNI-10-148
pmc: PMC6744806
doi:
Types de publication
Case Reports
Langues
eng
Pagination
148Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Surg Neurol. 2003 Jan;59(1):47-53; discussion 53-4
pubmed: 12633961
Ann Surg. 1960 Nov;152:804-8
pubmed: 13716736
J Neurooncol. 1992 Nov;14(3):277-87
pubmed: 1460491
Tumori. 2004 Mar-Apr;90(2):265-8
pubmed: 15237597
Zentralbl Neurochir. 2007 Aug;68(3):111-8
pubmed: 17665341
Aust N Z J Med. 1991 Dec;21(6):884-5
pubmed: 1818550
J Neurosurg. 2010 Aug;113(2):333-9
pubmed: 20367074
Crit Rev Oncol Hematol. 2011 Mar;77(3):163-71
pubmed: 20456972
J Neurosurg. 2011 Mar;114(3):747-55
pubmed: 20672899
Acta Neurochir (Wien). 2011 Feb;153(2):385-94
pubmed: 21104099
Cancer. 2011 Nov 1;117(21):4939-47
pubmed: 21480200
Clin Neurol Neurosurg. 2011 Nov;113(9):703-10
pubmed: 21872387
Acta Neurochir (Wien). 2012 Feb;154(2):237-48; discussion 248
pubmed: 21938461
Neurosurgery. 2013 Feb;72(2):203-9
pubmed: 23149953
Neurosurgery. 2013 Oct;73(4):624-30; discussion 630-1
pubmed: 23839520
J Clin Neurosci. 2014 Apr;21(4):612-5
pubmed: 24231562
World Neurosurg. 2014 Mar-Apr;81(3-4):556-62
pubmed: 24239740
Neuro Oncol. 2015 Jan;17(1):116-21
pubmed: 25100872
Clin Sarcoma Res. 2014 Sep 24;4:13
pubmed: 25276340
Am J Clin Oncol. 2017 Jun;40(3):223-227
pubmed: 25350465
J Clin Neurosci. 2015 Apr;22(4):718-25
pubmed: 25744076
Liver Int. 2015 Oct;35(10):2337
pubmed: 25913235
Case Rep Oncol Med. 2015;2015:214306
pubmed: 26090247
Clin J Gastroenterol. 2009 Feb;2(1):30-35
pubmed: 26191805
Int J Surg Case Rep. 2015;15:50-3
pubmed: 26318126
Clin Mol Hepatol. 2016 Mar;22(1):188-91
pubmed: 27044772
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neurosurgery. 1989 Oct;25(4):514-22
pubmed: 2797389
World Neurosurg. 2017 Aug;104:795-801
pubmed: 28552736
J Neurosurg. 2018 Jun;128(6):1719-1724
pubmed: 28644098
J Clin Neurosci. 2017 Oct;44:169-174
pubmed: 28711294
J Neurol Surg B Skull Base. 2017 Aug;78(4):324-330
pubmed: 28725519
J Neurosurg. 2018 Dec 1;129(6):1384-1396
pubmed: 29372881
J Neurooncol. 2018 May;138(1):173-182
pubmed: 29427152
J Neurooncol. 2018 Jul;138(3):447-467
pubmed: 29551003
Oncology. 2018;94(6):340-344
pubmed: 29614488
J Neurooncol. 2018 Sep;139(2):251-259
pubmed: 29675794
J Neurooncol. 2018 Sep;139(2):369-372
pubmed: 29700673
Acta Neuropathol. 2019 Feb;137(2):307-319
pubmed: 30584643
Surg Today. 1993;23(7):644-8
pubmed: 8369618
No Shinkei Geka. 1998 Mar;26(3):241-5
pubmed: 9558656